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1Diabetes Research Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, 2 Peripheral
Neuropathy Unit, Hammersmith Hospital, Imperial College London, London, United Kingdom, 3 Academic Unit of Radiology,
University of Sheffield, Sheffield, United Kingdom
Painful diabetic peripheral neuropathy can be intractable with a major impact, yet
the underlying pain mechanisms remain uncertain. A range of neuronal and vascular
biomarkers was investigated in painful diabetic peripheral neuropathy (painful-DPN) and
painless-DPN and used to differentiate painful-DPN from painless-DPN. Skin biopsies
were collected from 61 patients with type 2 diabetes (T2D), and 19 healthy volunteers
(HV). All subjects underwent detailed clinical and neurophysiological assessments. Based
on the neuropathy composite score of the lower limbs [NIS(LL)] plus seven tests,
the T2D subjects were subsequently divided into three groups: painful-DPN (n = 23),
painless-DPN (n = 19), and No-DPN (n= 19). All subjects underwent punch skin biopsy,
and immunohistochemistry used to quantify total intraepidermal nerve fibers (IENF) with
protein gene product 9.5 (PGP9.5), regenerating nerve fibers with growth-associated
protein 43 (GAP43), peptidergic nerve fibers with calcitonin gene-related peptide (CGRP),
and blood vessels with von Willebrand Factor (vWF). The results showed that IENF
density was severely decreased (p < 0.001) in both DPN groups, with no differences
for PGP9.5, GAP43, CGRP, or GAP43/PGP9.5 ratios. There was a significant increase
in blood vessel (vWF) density in painless-DPN and No-DPN groups compared to the
HV group, but this was markedly greater in the painful-DPN group, and significantly
higher than in the painless-DPN group (p < 0.0001). The ratio of sub-epidermal
nerve fiber (SENF) density of CGRP:vWF showed a significant decrease in painful-DPN
vs. painless-DPN (p = 0.014). In patients with T2D with advanced DPN, increased
dermal vasculature and its ratio to nociceptors may differentiate painful-DPN from
painless-DPN. We hypothesized that hypoxia-induced increase of blood vessels, which
secrete algogenic substances including nerve growth factor (NGF), may expose their
associated nociceptor fibers to a relative excess of algogens, thus leading to painful-DPN.
Keywords: pain, biomarkers, skin, vascular, painful diabetic neuropathy, von Willebrand Factor, IENFD, type 2
diabetes
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INTRODUCTION
Painful diabetic peripheral neuropathy affects up to a quarter
of all patients with diabetes (1) and can lead to a significant
curtailment of quality of life (2). Patients present with a
range of sensory symptoms, including burning, aching and
“electric shock-like” pains in their feet and legs (3). Night-time
exacerbations of pain and contact hypersensitivity to bedclothes
result in loss of sleep, and painful diabetic peripheral neuropathy
(painful-DPN) can be disabling (4).
The pathophysiology of painful-DPN is complex, and there
are no generally accepted disease-modifying treatments for the
condition (4). The mainstay of treatment is symptom control
with pharmacotherapy, which has limited efficacy and often dose-
limiting side effects (5). Thus, there is a need to understand
the underlying mechanisms of pain in DPN to help advance
its treatment.
Intraepidermal nerve fiber (IENF) density in skin biopsies,
using the pan-neuronal marker Protein Gene Product 9.5
(PGP9.5), is being used increasingly to diagnose small
fiber neuropathy (6). Both animal and human studies have
demonstrated a decrease in PGP 9.5 IENF density in DPN
(7, 8). However, IENF density assessed with PGP9.5 is unhelpful
in determining or predicting painful-DPN (9). Similarly,
psychophysical tests, such as Quantitative Sensory Testing
(QST) of small nerve fibers, may help diagnose DPN (10),
but do not predict the presence of neuropathic pain (11).
In recent studies, a more severe neuropathy was found in
patients with painful-DPN (12, 13). Recent study has also
implicated nerve fibers expressing calcitonin gene-related
peptide (CGRP) (14, 15), and the nerve regeneration marker
growth-associated protein 43 (GAP-43) (16, 17), in painful-
DPN. Further, the vasculature may play a role, as reported in
several studies. Increased sural nerve epineurial blood flow
was found in subjects with painful-DPN (18). In subjects
with treatment-induced painful neuropathy of diabetes, an
abundance of epineural blood vessels, resembling the new
vessels of the retina, was demonstrated (19). Impairment of
microvascular reactivity in foot skin was linked to pain in
diabetic neuropathy (20).
In this study, we have examined a panel of skin
nerve and vascular markers in carefully characterized
subjects with and without type 2 diabetes (T2DM) and
compared DPN patients with and without neuropathic
pain. We have used von Willebrand Factor (vWF), a
vascular endothelial cell marker, to quantify dermal
blood vessels (21).
Abbreviations: T2DM, type 2 diabetes; DPN, diabetic peripheral neuropathy;
DM, diabetes mellitus; HV, healthy volunteers; NISLL+7, Neuropathy
Impairment Score of the Lower Limb plus 7 tests of nerve function; DN4,
Douleur Neuropathique-4 painful neuropathy score; NPRS, Numeric Pain
Rating Scale; IENF, Intra Epidermal Nerve Fibre; SENF, Sub Epidermal
Nerve Fibre; CDT, Cooling Detection Threshold; WDT, Warm Detection
Threshold; TSL, Thermal Sensory Limen; ESC, Electrochemical Skin
Conductance; BMI, body mass index; ACR, albumin creatinine ratio; GFR,
glomerular filtration rate; PGP9.5, Protein Gene Product 9.5; GAP43, growth-
associated protein 43; CGRP, calcitonin gene-related peptide; vWF, von
Willebrand Factor.
MATERIALS AND METHODS
Study Design and Participants
The study group consisted of 80 Caucasian subjects were
included in this study: Healthy Volunteers (HV n = 19), and
T2D subjects (n = 61), those without neuropathy (No-DPN, n
= 19), with painless neuropathy (painless-DPN, n = 19), and
with painful neuropathy (painful-DPN, n = 23). Patients were
recruited from Sheffield Teaching Hospitals NHS Foundation
Trust Diabetes Database and diabetes outpatient clinics. All
patients had T2D diagnosed according to the WHO criteria (22).
Exclusion criteria included non-diabetic neuropathies, history
of alcohol consumption of more than 24 units a week, diabetic
neuropathies other than distal symmetrical polyneuropathy, a
peripheral vascular disease with absence of foot pulses, and
neurological or other systemic disorders. All subjects gave
written, informed consent before they participated in the study,
which had Ethics Approval by the Sheffield Research Ethics
Committee (Study Number STH15701).
Neuropathy Assessment
All subjects underwent: (1) evaluation of the Douleur
Neuropathique-4 (DN4) questionnaire (23); (2) Neuropathy
Impairment Score Lower Limb [NIS(LL)] to assess clinical
peripheral neurological status, (24); (3) Cardiac Autonomic
Function Tests (CAFTs) using the O’Brien protocol, (25); (4)
nerve conduction studies (NCS) of the sural, common peroneal,
and tibial nerves at a stable skin temperature of 31◦C and a
room temperature of 24◦C, using a Medelec electrophysiological
system (Synergy Oxford Instruments, Oxford, UK); (5) detailed
Quantitative Sensory Testing (QST), to assess large and small
fiber function according to the German Research Network
on Neuropathic Pain (DFNS) protocol (26), utilizing the
Medoc TSA 2 Neurosensory analyser (Medoc Ltd., Ramat
Yishai, Israel) (27); (6) sudomotor function assessment with
measurement of foot Electrochemical Skin Conductance (ESC)
using SUDOSCAN (Impeto Medical, Paris, France), as a marker
of peripheral autonomic small fiber neuropathy (28). They also
recorded average daily pain intensity scores for 7 days on an
11-point Numeric Pain Rating Scale (NPRS), ranging from 0 (no
pain at all) to 10 (worst imaginable pain), from which an average
daily pain score was calculated.
An overall Neuropathy Composite Score of NIS(LL)+7
was obtained by combining the NIS(LL) plus seven tests of
nerve function (29). This is a validated, composite measure
of neuropathy severity that has been used in epidemiological
and population-based studies. Based on these assessments and
the DN4 questionnaire score (12), participants with T2D were
divided into three groups:
1) No-DPN, T2D consisting of asymptomatic participants with
normal clinical and neurophysiological assessments.
2) Painless-DPN, comprising of pain-free participants with
distal symmetrical polyneuropathy (1, 30).
3) Painful-DPN, participants with painful neuropathic
symptoms involving the feet and/or legs in a distal
symmetrical fashion together with evidence of peripheral
neuropathy (1).
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TABLE 1 | Demographic characteristics (mean/SD for normally distributed variables and median/interquartile range for nonparametric variables) of study subjects.
HV No–DPN Painless–DPN Painful–DPN p Value ANOVA
n 19 19 19 23
Age (years) 55.1 (10.6) 58.3 (8.6) 60.8 (10.0) 60.2 (10.2) 0.27
Gender (male %) 47.3 52.6 68.0 56.5 0.61
BMI (kg/m2 ) 26.8 (4.2) 31.5 (6.1) 30.3 (5.2) 33.7 (5.4) 0.001
Diabetes duration (years)* – 8.0 (6.5) 14.5 (16.2) 13.0 (19.5) 0.24
HbA1c (mmol/mol) – 63.3 (20.0) 61.5 (8.0) 66.9 (13.8) 0.51
Urine ACR (mg/mmol)* – 0.8 (0.9) 1.7 (7.2) 4.6 (22.3) 0.13
eGFR (mls/min/1.73m2 ) – 73 (13.9) 68.1 (20.1) 61.6 (19.6) 0.30
DPN, diabetic peripheral neuropathy; DM, diabetes mellitus, HV, healthy volunteers; BMI, body mass index; ACR, albumin creatinine ratio; GFR, glomerular filtration rate.
* non-parametric variables.
Skin Biopsy
Skin biopsy specimens were obtained from the distal leg (10 cm
above the lateral malleolus), in line with the guidelines published
by the European Federation of Neurological Societies (EFNS) on
the use of skin biopsy in the diagnosis of peripheral neuropathies
(6). The skin was anesthetized by local infiltration of 2% lidocaine
before a 3mm punch biopsy was collected.
Immunohistochemistry
The skin biopsy specimen was fixed for 12–18 h in
paraformaldehyde-lysine-periodate and cryoprotected overnight
(15% sucrose in.1M phosphate buffer) at 4◦C, then snap-frozen
in liquid nitrogen. Then, 15 µm tissue sections were collected
with a freezing microtome for assessment of intra-epidermal
(IENF) and sub-epidermal (SENF) nerve fiber density (30µm
thickness for GAP-43 to increase the sensitivity of this marker
in the epidermis). Sections were incubated overnight with
primary antibodies to the structural pan-neuronal marker
PGP9.5 (1:40,000; Ultraclone, Isle of Wight, UK), the marker
of regenerating nerve fibers GAP-43 (1:80,000; Sigma-Aldrich,
Dorset, UK), the sensory neuropeptide CGRP (1:2,000;
Novocastra Ltd, Newcastle Upon Tyne, UK), and to the vascular
marker vWF (1:10,000; Novocastra Laboratories, Milton Keynes,
UK). They were then detected using avidin-biotin-peroxidase
methods (ABC; Vector Laboratories, Peterborough, UK) giving
black, positive immunostaining as previously described, and
validated for the section thickness used, i.e., 15 µm compared
with 50 µm, the former section thickness enables a range of
markers to be studied in the same biopsy (31–33). Tissue sections
were counterstained for nuclei in 1% w/v aqueous neutral red.
Omission of primary antibodies and sequential dilution of
antibodies gave appropriate results for specificity.
Intraepidermal nerve fibers were counted along the length of
four non-consecutive sections. The length of epithelium in each
counted section was measured using computerized microscopy
software (Olympus ANALYSIS 5 Soft, Olympus UK, Southend,
Essex, UK), and results were expressed as fibers/mm length
of the section. SENF was measured by image analysis, where
digital photomicrographs were captured via video link to an
Olympus BX50 microscope (Olympus Optical Co. Ltd., Tokyo,
Japan) with a depth of 200 µm below the basal epidermis.
The gray-shade detection threshold was set at a constant level
to allow detection of positive immunostaining and the area of
highlighted immunoreactivity was obtained as a percentage (%
area) of the field scanned. Images were captured (×40 objective
magnification) along the entire length and the mean values were
used for statistical analysis. Quantification was performed by
two independent blinded observers and there was no significant
difference between observers.
Statistical Analysis
The statistical package SPSS version 24 (SPSS, IBM Corp, NY,
USA) was used for baseline data, and GraphPad Prism version
5 for Windows (GraphPad Prism Software, San Diego, CA,
USA) for skin biopsy data. Baseline subject characteristics were
described as mean and SDs for normally distributed variables, as
the median and interquartile range for variables with a skewed
distribution, and percentages for categorical variables. We have
used Spearman’s rank correlation for non-parametric variables.
One-way ANOVA was used to compare the mean of baseline
characteristics. Skin biopsy data were analyzed using Mann–
Whitney U test and p <0.05 (two-tailed) indicated significance.
RESULTS
Table 1 summarizes demographic details and study assessments
performed for each group. The groups were matched for age
and gender. The diabetes patient groups had a higher body
mass index (BMI, ANOVA p < 0.01) compared with HV. There
was no statistically significant difference in duration of diabetes
and HbA1c among the diabetes groups. Table 2 shows clinical,
neurophysiological, quantitative sensory testing, and skin biopsy
data of the different groups. As expected, the DPN groups had
significantly higher NISLL+7 scores compared with the No-DPN
and HV groups. The painful-DPN group had a higher NISLL+7
score compared with the painless-DPN group (as reported
previously). The DN4 score and 24-h numeric pain rating scale
(NPRS) pain score was significantly higher in the painful-DPN
group compared with all the other groups (p < 0.01). While
warm detection thresholds (WDT) were significantly raised in
both DPN groups (p < 0.01), with no differences between
painful- and painless-DPN, cold detection threshold (CDT)
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TABLE 2 | Clinical parameters of study subjects [mean(SD)].
HV No-DPN Painless DPN Painful DPN p Value ANOVA
NISLL+7 0.5 (0.8) 1.4 (1.2) 19.6 (7.6) 28.9 (16.4) <0.01
DN4 0 0.1 (0.5) 2.1 (0.8) 5.9 (1.8) <0.01
NPRS 0 0 0 7.06(1.7) <0.01
CDT (◦C) 27.1 (3.2) 25.0 (3.2) 19.5 (10.6) 11.2 (10.6) <0.01
WDT (◦C) 39.3 (3.6) 39.6 (3.5) 46.4 (3.9) 47.2 (3.0) <0.01
TSL (◦C) 13.6 (7.2) 17.09 (8.7) 30.9 (12.0) 37.9 (12.3) <0.01
Feet ESC (µS) 80.7 (7.6) 70.5 (17.8) 45.3 (24.5) 50.3 (27.7) <0.01
SNCV (m/s) 48.8 (11.1) 44.4 (6.5) 16.4 (20.7) 15.1 (19.1) <0.01
Sural Amplitude (mA) 15.7 (7.5) 12.4 (5.6) 2.3 (3.2) 2.9 (3.6) <0.01
CPCV (m/s) 46.7 (4.2) 43.4 (4) 37.6 (23.8) 23.6 (20.4) <0.01
CP Amplitude (mA) 5.6 (1.9) 4.6 (1.9) 2.4 (2.3) 1.5 (1.7) <0.01
Tibial Latency (ms) 4.2(0.9) 4.2 (0.6) 5.7 (2.8) 3.6 (3.7) 0.2
IENFD (fibers/mm) 5.6 (1.3) 5.3 (3.1) 0.63 (1.4) 0.82 (1.7) <0·01
SENFD (% area) 1.0 (0.4) 1.6 (0.9) 0.35 (0.6) 0.14 (0.2) <0.01
DPN, diabetic peripheral neuropathy; DM, diabetes mellitus; HV, healthy volunteers; NISLL+7, Neuropathy Impairment Score of the Lower Limb plus 7 tests of nerve function; DN4,
Douleur Neuropathique-4 painful neuropathy score; NPRS, Numeric Pain Rating Scale; IENFD, Intra Epidermal Nerve Fiber Density; SENFD, Sub Epidermal Nerve.
Fiber Density; CDT, Cooling Detection Threshold; WDT, Warm Detection Threshold; TSL, Thermal Sensory Limen; ESC, Electrochemical Skin Conductance; SNCV, Sural Nerve
Conduction Velocity; CPCV, Common Peroneal Conduction Velocity; CP, Common Peroneal.
was significantly reduced in the painful-DPN compared with
painless-DPN (p < 0.01). There was also a significant increase
in thermal sensory limen (TSL) in painful-DPN (p < 0.01).
SUDOSCAN foot electrochemical skin conductance, a measure
of autonomic sudomotor function, was significantly reduced in
DPN groups compared with No-DPN and HV groups (Feet ESC,
ANOVA p < 0.01) but post-hoc analysis showed no difference
between painful and painless-DPN groups (Feet ESC, LSD p =
0.45). Calf skin IENFD and SENFD were severely diminished in
both DPN groups, with no differences between the two.
Protein Gene Product 9.5
Immunostaining for the pan-neuronal marker (PGP 9.5) in
skin biopsies from the HV and No-DPN groups showed
sub-epidermal nerve fascicles (SENF) adjacent to the basal
epidermis, with IENF emerging from them (Figure 1). These
were markedly and significantly reduced in both DPN groups,
with pain or without pain (p < 0.0001). Image analysis of
sub-epidermal PGP9.5-immunoreactive nerve fibers (SENF) in
both painful-DPN and painless-DPN also showed a similar
reduction compared to the HV group (SENF, p < 0.0001 and p=
0.0001, respectively). However, there was no statistical difference
between HV vs. No-DPN groups, and painless-DPN vs. painless
DPN groups, for both IENF and SENF analyses.
Growth-Associated Protein 43
Immunostaining for the nerve regeneration marker (GAP43)
in skin biopsies from the HV group showed a similar pattern
to PGP9.5 (Figure 2). GAP43 IENF density was significantly
reduced in both painful-DPN (p = 0.0026) and painless-DPN
groups (p < 0.001) compared with the HV group. Image
analysis of sub-epidermal GAP43-immunoreactive nerve fibers
(SENF) in painful-DPN and painless-DPN groups also showed
a similar reduction compared to the HV group (SENF GAP-
43, p < 0.002 and p = 0.001, respectively); again, there was
no statistical difference between HV vs. No-DPN groups, or for
painful-DPN vs. painless-DPN groups, for both IENF and SENF
GAP43 analyses.
Calcitonin Gene-Related Peptide
Immunostaining for CGRP showed severely diminished IENF
density, so only SENF were quantified (Figure 3). The CGRP
image analysis also showed a similar decrease in both DPN
groups (painful-DPN, p < 0.0001; painless-DPN, p = 0.0001)
compared with the HV group. There was no statistical difference
between the painful-DPN and painless-DPN groups for SENF
CGRP analyses.
Von Willebrand Factor
Immunostaining for the vascular marker, vWF, showed increased
sub-epidermal staining area in all diabetes groups vs. the HV
group (Figure 4). There was a highly significant increase in
the vascular staining in both groups with DPN compared to
the HV group (painful-DPN, p < 0.0001; painless-DPN, p =
0.0037), and also in the No-DPN group (p = 0.02), compared
with the HV group. There was significant correlation of vWF
to QST parameters especially to thermal thresholds, CDT and
HPT (CDT; cc = −0.379, p < 0.004, HPT; r = 0.435, p =
0.002) (Table 3) and DN4 pain score (DN4; cc = 0.632, p <
0.0001). Expressing the results as a ratio of PGP9.5 (SENF) to
vWF showed similar results in painful-DPN (p < 0.0001) and
painless-DPN (p = 0.0003), but not with the no-DPN group (p
= 0.72) (Figure 5A). Similarly, expressing the results as a ratio
of GAP43 (SENF) to vWF showed similar results in the painful-
DPN (p = 0.0004) and painless-DPN (p = 0.002) groups, but
not with the No-DPN group (p = 0.31) (Figure 5B). Expressing
the results as a ratio of CGRP (SENF) to vWF showed similar
Frontiers in Pain Research | www.frontiersin.org 4 October 2021 | Volume 2 | Article 731658
Shillo et al. Biomarkers of Painful Diabetic Neuropathy
FIGURE 1 | (a) Protein gene product 9.5 (PGP9.5) immunoreactivity in calfskin from healthy volunteers, HV, (b) painful-diabetic peripheral neuropathy (DPN), (c)
painless-DPN, and (d) No-DPN. (e) Mean ± SEM of the PGP9.5 intra-epidermal fibers (fibers/mm). (f) Image analysis of PGP9.5 sub-epidermal counts (%
immunoreactivity) in the same groups (HV, painful-DPN, painless-DPN, No-DPN).
results (painful-DPN, p < 0.0001, painless-DPN, p = 0.0002),
and a significant decrease with the No-DPN group (p = 0.02)
(Figure 5C) compared with HV. The ratio of sub-epidermal
nerve fiber (SENF) density of CGRP:vWF showed a significant
decrease in the painful-DPN group vs. painless-DPN group (p =
0.014) (Figure 5C), but this was not significant for ratios of the
other nerve markers.
DISCUSSION
In this study, we reported significant nerve fiber loss in distal
leg skin biopsies from patients with DPN using PGP9.5, CGRP,
and GAP43 nerve fiber immunostaining. This was apparent for
IENF and SENF density in both painful-DPN and painless-DPN
groups, compared with the HV group, and patients without the
No-DPN group. In contrast, there was a significant increase
in the vascular marker vWF in skin biopsies from all diabetes
(T2DM) groups, which was particularly marked in the painful-
DPN group. Importantly, this increase of blood vessels was
significantly greater in the painful-DPN than the painless-DPN
group. There was a significant correlation of vWF to thermal
thresholds especially CDT and HPT also to DN4 pain score
supporting vascular etiology in painful-DPN and predominant
involvement of small fibers.
Our finding of similarly reduced PGP9.5 IENF density in
painful-DPN and painless-DPN groups agrees with previous
studies (16, 32, 34). The severity of IENF loss was indicative
of advanced DPN in both our painful-DPN and painless-DPN
groups. GAP43, the selective marker for regenerating nerve
fibers, was decreased in DPN, as in previous studies (32, 34).
Studies of skin biopsies from proximal thigh showed higher
GAP43:PGP ratios in painful-DPN compared with painless-DPN
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FIGURE 2 | (a) Growth-associated protein 43 (GAP43) immunoreactivity in calfskin from healthy volunteers, HV, (b) painful-DPN, (c) painless-DPN, and (d) No-DPN.
(e) Mean ± SEM of the GAP-43 intra-epidermal fibers (fibers/mm). (f) Image analysis of GAP43 sub-epidermal counts (% immunoreactivity).
subjects (16, 17). However, this was not observed in our cohort
with advanced DPN in distal leg skin biopsies, and future studies
are indicated in mild/early DPN.
Our further analyses, comparing nerve fiber density to
the vascular marker, vWF, showed that CGRP to vWF ratio
was lower in painful-DPN than in painless-DPN. Hence, we
hypothesized that in advanced painful DPN, the increased
dermal vasculature, and its ratio to reduced/surviving
nociceptors, i.e., CGRP-expressing small sensory nerve
fibers, may differentiate painful-DPN from painless-DPN.
Increased blood vessels following tissue ischaemia and
hypoxia, associated with disproportionate, i.e., relatively
fewer, CGRP nociceptor nerve fibers, may lead to painful-
DPN. While the % ratio of CGRP to vWF of no-DPN
vs. HV was significantly reduced, this reduction was
greater in DPN, particularly painful-DPN. These proposed
mechanisms and the supportive evidence (35–38) were
discussed below.
The density of IENF is known to be decreased in a wide
range of neuropathic pain syndromes, including postherpetic
neuralgia (PHN), painful-DPN, and painful HIV-associated
neuropathy (38). Further, it is now widely accepted that
the residual/surviving nociceptors may develop hyperexcitable
properties, due to exposure to relatively high concentrations of
Nerve Growth Factor (NGF) and other algogens (37, 38). We
originally proposed that disproportionately high NGF levels in
the target organ and its surviving nociceptors expressing its high-
affinity receptor TrkAmay underlie neuropathic pain (36). These
surviving nociceptors may correspond to the later description
of “irritable nociceptors” in PHN skin (39), or “over-trophed
nociceptors”. In normal human skin, NGF is predominantly
produced and secreted by keratinocytes and blood vessels (35,
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37). NGF is up-regulated by inflammation, wherein nociceptor
terminals in skin exposed to higher NGF become hyperactive
and sprout, resulting in pain and hypersensitivity (36). These
processes and interactions are more complex in different stages
of painful neuropathies (37, 38). We had previously shown a
decrease in CGRP nociceptors, which were regulated by nerve
growth factor (NGF), and also reduced NGF expression in early
DPN (35). However, a relative excess of NGF, so akin to the
NGF to TrkA nerve fiber disproportion in inflammation, may
sensitize residual CGRP nociceptors, and lead to neuropathic
FIGURE 3 | (a) Calcitonin gene-related peptide (CGRP) immunoreactivity in
calfskin from healthy volunteers HV, (b) painful-DPN (c) painless-DPN, and (d)
No-DPN. (e) Image analysis of CGRP sub-epithelial counts (%
immunoreactivity) in the same groups (HV, painful-DPN, painless-DPN,
no-DPN). Intra-epithelial fibers were absent or sparse in all groups.
pain (36–38). Thus, at the early stage of DPN, the ratio of
NGF in keratinocytes to residual dying-back IENF may underlie
hypersensitivity. At the late stage of advanced DPN, with marked
or complete loss of IENF as in this study, the increased ratio
of blood vessels to associated dermal nociceptors (SENF), e.g.,
those which express CGRP, may contribute to the development
of neuropathic pain. The algogens related to increased blood
vessels may include NGF, secreted from the blood vessels
themselves, as well as NGF and cytokines, secreted by Schwann
and inflammatory cells, consequent to nerve degeneration (35–
38). Future studies should include assessment of NGF levels and
their potential role in angiogenesis, and contribution of local or
circulating inflammatory cells, at different stages of painful-DPN.
FIGURE 4 | (a) von Willebrand Factor (vWF) immunoreactivity in calfskin from
healthy volunteers, HV (b), painful-DPN (c) painless-DPN, (d) No-DPN, (e)
image analysis of vWF sub-epithelial endothelial staining (% immunoreactivity).
TABLE 3 | Correlation Coefficients of SE PGP, IE PGP, and combined IE/SE corrected vWF to QST parameters.
CDT WDT TSL CPT HPT PPT VDT
vWF/*SE PGP CC −0.379 0.265 0.203 −0.168 0.435 0.093 0.209
P value 0.004 0.049 0.134 0.216 0.001 0.494 0.121
vWF/*IE PGP CC −0.351 0.223 0.159 −0.133 0.395 0.116 −0.127
P value 0.008 0.099 0.242 0.330 0.003 0.393 0.350
vWF/*IE and SE PGP CC −0.349 0.207 0.150 −0.125 0.395 0.102 −0.132
P value 0.009 0.130 0.275 0.363 0.003 0.457 0.337
vWF, von Willibrand factor; IE, Intra Epidermal; SE, Sub Epidermal; CDT, Cooling Detection Threshold; WDT, Warm Detection Threshold; TSL, Thermal Sensory Limen; CPT, Cold Pain
Threshold; HPT, Heat Pain Threshold; PPT, Pressure Pain Threshold; VDT, Vibration Detection Threshold.
*covariates used in the analyses. IE, intraepidermal, SE, subepidermal. Significant results (p < 0.05) are shown in bold.
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FIGURE 5 | Bar charts showing image analyses (mean ± SEM) of (A) PGP9.5
sub-epidermal nerve fiber (SENF) (SEF): vWF, (B) GAP43 SENF: vWF, and (C)
CGRP SENF: vWF ratios.
We have reported similar changes in subjects with painful
non-freezing cold injury (NFCI or Trench Foot). Distal leg skin
biopsies from patients with chronic NFCI showed a marked
increase of blood vessels, as indicated by the immunostaining
for vWF and also vascular endothelial growth factor (VEGF).
The increased vasculature may reflect the changes secondary to
hypoxia and ischaemia, with the formation of new blood vessels,
as indicated by increased VEGF (38), which in NFCI may be
induced by cold and mechanical pressure. The ratios of nerve
markers to vWF were also decreased in painful NFCI calfskin,
as in painful-DPN in this study.
Our previous studies in patients with painful-DPN
have reported involvement of the vasculature: increased
peripheral nerve epineurial blood flow (18), altered foot skin
microcirculation (20), increased thalamic vascularity (40), and
autonomic dysfunction (41). Laser Doppler studies have shown
altered capillary circulation in the feet of patients with DPN (42).
Increased plasma vWF has been associated with neuropathic
foot ulceration (43). In addition to the vasculature, thalamic
neurotransmitter mechanisms (44) and metabolic factors such as
Vitamin D (45) may also play a role in painful-DPN.
Our results indicated that further studies are required,
particularly of underlying neuro-vascular mechanisms, which
may help to improve our understanding of neuropathic pain
development and its treatment.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Sheffield Research Ethics Committee. The
patients/participants provided their written informed consent to
participate in this study.
AUTHOR CONTRIBUTIONS
PS conducted the clinical study. YY and PD analyzed the tissues
and all wrote the manuscript. MG, DS, and IW helped set up the
study and contributed to the discussion. PA and ST conceived
and supervised the study and wrote the manuscript. All authors
contributed to the article and approved the submitted version.
FUNDING
ST thanks Sheffield Teaching Hospitals Diabetes Charitable Trust
for funding the study.
ACKNOWLEDGMENTS
Some content of this manuscript has been published as part
of the MD thesis of PS, Shillo et al. (45). The content of this
manuscript has been also presented in part at the American
Frontiers in Pain Research | www.frontiersin.org 8 October 2021 | Volume 2 | Article 731658
Shillo et al. Biomarkers of Painful Diabetic Neuropathy
Diabetes Association (ADA) 77th Scientific Sessions 2017,
Diabetes UK Professional Conference 2017, NEURODIAB 2017,
and NEURODIAB 2015. PA thanks the Biomedical Research
Center, Imperial College London, for its facilities. The authors
thankDrs. Rosario Privitera andGordon Sloan for their help with
preparing the manuscript.
REFERENCES
1. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler
P, et al. Diabetic neuropathies: update on definitions, diagnostic
criteria, estimation of severity, and treatments. Diabetes Care. (2010)
33:2285. doi: 10.2337/dc10-1303
2. Sloan G, Shillo P, Selvarajah D, Wu J, Wilkinson ID, Tracey I, et al. A
new look at painful diabetic neuropathy. Diabetes Res Clin Pract. (2018)
144:177–91. doi: 10.1016/j.diabres.2018.08.020
3. Shillo P, Sloan G, Greig M, Hunt L, Selvarajah D, Elliott J, et al. Painful and
painless diabetic neuropathies: what is the difference? Curr Diab Rep. (2019)
19:32. doi: 10.1007/s11892-019-1150-5
4. Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical
management of diabetic sensorimotor peripheral neuropathy. Nature Review
Endocrinol. (2021) 17:400–20.
5. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M,
et al. Painful diabetic peripheral neuropathy: consensus recommendations
on diagnosis, assessment and management. Diabetes Metab Res Rev. (2011)
629–38. doi: 10.1002/dmrr.1225
6. Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, et
al. European Federation of Neurological Societies/ Peripheral Nerve Society
Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy.
Report of a joint task force of the European Fe-deration of Neurological
Societies and the Peripheral Nerve Society. Eur J Neurol. (2010) 17:903–
E49. doi: 10.1111/j.1468-1331.2010.03023.x
7. Kennedy WR. Wendelschafer-crabb G, Johnson T, Wendelschafer-Crabb G.
Quantitation of epidermal nerves in diabetic neuropathy. Neurology. (1996)
47:1042. doi: 10.1212/WNL.47.4.1042
8. Shun C-t, Chang Y-c, Wu H-p, Hsieh S-c, Lin W-m, Lin Y-h, et al. Skin
denervation in type 2 diabetes: correlations with diabetic duration and
functional impairments. Brain. (2004) 127:1593. doi: 10.1093/brain/awh180
9. Sorensen L, Molyneaux L, Yue DK. The level of small nerve
fiber dysfunction does not predict pain in diabetic Neuropathy:
a study using quantitative sensory testing. Clin J Pain. (2006)
22:261. doi: 10.1097/01.ajp.0000169670.47653.fb
10. Coppini DV, Wellmer A, Weng C, Young PJ, Anand P, Sönksen PH. The
natural history of diabetic peripheral neuropathy determined by a 12 year
prospective study using vibration perception thresholds. J Clin Neurosci.
(2001) 8:520–4. doi: 10.1054/jocn.2001.0893
11. Sorensen L, Molyneaux L, Yue DK. The relationship among pain,
sensory loss, and small nerve fibers in diabetes. Diabetes Care. (2006)
29:883. doi: 10.2337/diacare.29.04.06.dc05-2180
12. Themistocleous AC, Ramirez JD, Shillo PR, Lees JG, Selvarajah D,
Orengo C, et al. The Pain in Neuropathy Study (PiNS): a cross-
sectional observational study determining the somatosensory phenotype
of painful and painless diabetic neuropathy. Pain. (2016) 157:1132–
45. doi: 10.1097/j.pain.0000000000000491
13. Raputova J, Srotova I, Vlckova E, Sommer C, Üçeyler N, Birklein
F, et al. Sensory phenotype and risk factors for painful diabetic
neuropathy: a cross-sectional observational study. Pain. (2017)
158:2340–53. doi: 10.1097/j.pain.0000000000001034
14. Cheng HT, Dauch JR, Hayes JM, Yanik BM, Feldman EL. Nerve
growth factor/ p38 signaling increases intraepidermal nerve fiber
densities in painful neuropathy of type 2 diabetes. Neurobiol Dis. (2012)
45:280. doi: 10.1016/j.nbd.2011.08.011
15. Cheng HT, Dauch JR, Hayes JM, Hong Y, Feldman EL. Nerve
growth factor mediates mechanical allodynia in a mouse model
of type 2 diabetes. J Neuropathol Exp Neurol. (2009) 68:1229–
43. doi: 10.1097/NEN.0b013e3181bef710
16. Cheng HT, Dauch JR, Porzio MT, Yanik BM, Hsieh W, Smith AG, et
al. Increased axonal regeneration and swellings in intraepidermal nerve
fibers characterize painful phenotypes of diabetic neuropathy. J Pain. (2013)
14:941. doi: 10.1016/j.jpain.2013.03.005
17. Bönhof GJ, Strom A, Püttgen S, Ringel B, Brüggemann J, Bódis K, et al.
Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes
with painful and painless polyneuropathy. Diabetologia. (2017) 60:2495–
503. doi: 10.1007/s00125-017-4438-5
18. Eaton SEM, Harris ND, Ibrahim S, Patel KA, Selmi F, Radatz
M, et al. Increased sural nerve epineurial blood flow in human
subjects with painful diabetic neuropathy. Diabetologia. (2003)
46:934. doi: 10.1007/s00125-003-1127-3
19. Tesfaye S, Malik R, Harris N, Jakubowski JJ, Mody C, Rennie IG, et al. Arterio-
venous shunting and proliferating new vessels in acute painful neuropathy
of rapid glycaemic control (insulin neuritis). Diabetologia. (1996) 39:329–
35. doi: 10.1007/BF00418349
20. Quattrini C, Harris ND, Malik RA, Tesfaye S. Impaired skin microvascular
reactivity in painful diabetic neuropathy. Diabetes Care. (2007)
30:655. doi: 10.2337/dc06-2154
21. Yamamoto K, de Waard V, Fearns C, Loskutoff DJ. Tissue distribution and
regulation of murine von Willebrand factor gene expression in vivo. Blood.
(1998) 92:2791–801. doi: 10.1182/blood.V92.8.2791
22. WHO. Definition and diagnosis of diabetes mellitus and intermediate
hyperglycaemia. Report of a WHO/IDF consultation. WHO (2006). Available
online at: http://www.who.int/diabetes/publications/definition%20and
%20diagnosis%200f%20diabetes_new.pdf
23. Spallone V, Morganti R, D’Amato C, Greco C, Cacciotti
L, Marfia GA. Validation of DN4 as a screening tool
for neuropathic pain in painful diabetic polyneuropathy.
Diabet Med. (2012) 29:578–85. doi: 10.1111/j.1464-5491.2011.
03500.x
24. Dyck PJ, Litchy WJ, Daube JR, Harper CM, Dyck PJB, Davies J, et
al. Individual attributes versus composite scores of nerve conduction
abnormality: Sensitivity, reproducibility, and concordance with
impairment. Muscle Nerve. (2003) 27:202–10. doi: 10.1002/mus.
10320
25. England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA,
et al. Practice Parameter: evaluation of distal symmetric polyneuropathy:
role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-
based review). Report of the American Academy of Neurology, American
Association of Neuromuscular and Electrodiagnostic Medicine, and
American Academy of Physical Medicine and Rehabilitation. Neurology.
(2009) 72:177. doi: 10.1016/j.pmrj.2008.11.011
26. Pfau DB, Geber C, Birklein F. Treede R-d, Treede R-D. Quantitative
sensory testing of neuropathic pain patients: potential mechanistic
and therapeutic implications. Current Pain and Headache Rep. (2012)
16:199. doi: 10.1007/s11916-012-0261-3
27. Rolke R, Baron R, Maier C, Tölle TR, Treede RD, Beyer A, et al. Quantitative
sensory testing in the German Research Network on Neuropathic Pain
(DFNS): Standardized protocol and reference values. Pain. (2006) 123:231–
43. doi: 10.1016/j.pain.2006.01.041
28. Casellini CM, Parson HK, Richardson MS, Nevoret ML, Vinik AI.
Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy
and autonomic dysfunction. Diabetes Technology & Therapeutics. (2013)
15:948. doi: 10.1089/dia.2013.0129
29. Dyck PJ, Peroutka S, Rask C, Burton E, Baker MK, Lehman KA, et al.
Intradermal recombinant human nerve growth factor induces pressure
allodynia and lowered heat- pain threshold in humans. Neurology. (1997)
48:501–5. doi: 10.1212/WNL.48.2.501
30. Dyck PJ, Davies JL, Litchy WJ. brien PC, Brien PC. Longitudinal
assessment of diabetic polyneuropathy using a composite score in
the Rochester Diabetic Neuropathy Study cohort. Neurology. (1997)
49:229. doi: 10.1212/WNL.49.1.229
Frontiers in Pain Research | www.frontiersin.org 9 October 2021 | Volume 2 | Article 731658
Shillo et al. Biomarkers of Painful Diabetic Neuropathy
31. Facer P, Mann D, Mathur R, Pandya S, Ladiwala U, Singhal B, et al. Do
nerve growth factor-related mechanisms contribute to loss of cutaneous
nociception in leprosy? Pain. (2000) 85:231–8. doi: 10.1016/S0304-395999
00273-0
32. Narayanaswamy H, Facer P, Misra VP, Timmers M, Byttebier G, Meert T, et
al. A longitudinal study of sensory biomarkers of progression in patients with
diabetic peripheral neuropathy using skin biopsies. J Clini Neurosci.. (2012)
19:1490. doi: 10.1016/j.jocn.2011.12.026
33. Anand P, Privitera R, Yiangou Y, Donatien P, Birch R, Misra P. Trench
foot or non-freezing cold injury as a painful vaso-neuropathy: clinical and
skin biopsy assessments. Front Neurol. (2017) 8:514. doi: 10.3389/fneur.2017.
00514
34. Quattrini C, Tavakoli M, Jeziorska M, Kallinikos P, Tesfaye S, Finnigan J, et
al. Surrogate markers of small fiber damage in human diabetic neuropathy.
Diabetes. (2007) 56:2148–54. doi: 10.2337/db07-0285
35. Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE,
Sinicropi DV. The role of endogenous nerve growth factor in human diabetic
neuropathy. Nat Med. (1996) 2:703–7. doi: 10.1038/nm0696-703
36. Anand P. Nerve growth factor regulates nociception in human health and
disease. Br J Anaesth. (1995) 75:201–8. doi: 10.1093/bja/75.2.201
37. Anand P. Neurotrophic factors and their receptors in human
sensory neuropathies. Prog Brain Res. (2004) 146:477–
92. doi: 10.1016/S0079-61230346030-5
38. Anand P, Bley K. Topical capsaicin for pain management: therapeutic
potential and mechanisms of action of the new high-concentration capsaicin
8% patch. Br J Anaesth. (2011) 107:490–502. doi: 10.1093/bja/aer260
39. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia:
irritable nociceptors and deafferentation. Neurobiol Dis. (1998)
5:209–27. doi: 10.1006/nbdi.1998.0204
40. Selvarajah D, Wilkinson ID, Gandhi R, Griffiths PD, Tesfaye S. Microvascular
perfusion abnormalities of the Thalamus in painful but not painless diabetic
polyneuropathy: a clue to the pathogenesis of pain in type 1 diabetes. Diabetes
Care. (2011) 34:718–20. doi: 10.2337/dc10-1550
41. Gandhi RA, Marques JL, Selvarajah D, Emery CJ, Tesfaye S.
Painful diabetic neuropathy is associated with greater autonomic
dysfunction than painless diabetic neuropathy. Diabetes Care. (2010)
33:1585–90. doi: 10.2337/dc09-2314
42. Netten PM, Wollersheim H, Thien T, Lutterman JA. Skin microcirculation
of the foot in diabetic neuropathy. Clin Sci (Lond). (1996) 91:559–
65. doi: 10.1042/cs0910559
43. Aso Y, Fujiwara Y, Tayama K, Inukai T, Takemura Y. Elevation
of von Willebrand factor in plasma in diabetic patients
with neuropathic foot ulceration. Diabet Med. (2002) 19:19–
26. doi: 10.1046/j.1464-5491.2002.00608.x
44. Selvarajah D, Wilkinson ID, Emery CJ, Shaw PJ, Griffiths PD, Gandhi R, et al.
Thalamic neuronal dysfunction and chronic sensorimotor distal symmetrical
polyneuropathy in patients with type 1 diabetes mellitus. Diabetologia. (2008)
51:2088–92. doi: 10.1007/s00125-008-1139-0
45. Shillo P, Selvarajah D, GreigM, Gandhi R, Rao G,Wilkinson ID, et al. Reduced
vitamin D levels in painful diabetic peripheral neuropathy.DiabetMed. (2019)
36:44–51. doi: 10.1111/dme.13798
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Shillo, Yiangou, Donatien, Greig, Selvarajah, Wilkinson, Anand
and Tesfaye. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pain Research | www.frontiersin.org 10 October 2021 | Volume 2 | Article 731658
